Note 6 - Intangible Assets

3 Months Ended

Mar. 31, 2014

Disclosure Text Block [Abstract]

Intangible Assets Disclosure [Text Block]

Note 6—Intangible Assets

 The value of the Company’s intangible assets is summarized below:

	Bertilimumab iCo			NanomAbs Yissum			Human Antibodies Kadouche			Anti-ferritin Antibody MabLife			Total
Balance as of December 31, 2012	$	2,254		$	613		$	615		$	414		$	3,896
Additions		—			—			—			—			—
Amortization		(167	)		(46	)		(47	)		(29	)		(289	)
Balance, December 31, 2013	$	2,087		$	567		$	568		$	385		$	3,607
Additions (see Note 8 (5))		—			—			—			111			111
Amortization		(42	)		(11	)		(12	)		(9	)		(74	)
Balance, March 31, 2014	$	2,045		$	556		$	556		$	487		$	3,644

The Company’s intangible assets were determined by management to have a useful life of between seven and fifteen years. Amortization expense amounted to $74 and $71 for the three month period ended March 31, 2014 and 2013 and to $806 for the cumulative period from Inception through March 31, 2014.

Estimated amortization expense for each of the five succeeding years, based upon intangible assets owned at March 31, 2014 is as follows:

Period Ending		Amount
2014	$	229
2015		305
2016		305
2017		305
2018 and thereafter		2,500
Total	$	3,644